NCT01187966View on ClinicalTrials.gov

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

669

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

February 28, 2009

Conditions
Parkinson's Disease
Interventions
DRUG

Safinamide

DRUG

Safinamide

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT01187966 - Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease | Biotech Hunter | Biotech Hunter